ANG-3070

DRUG2 trials

Sponsors

Angion Biomedica Corp

Conditions

Glomerular DiseaseIdiopathic Pulmonary Fibrosis (IPF)Proteinuria

Phase 1

Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis

Angion Biomedica CorpIdiopathic Pulmonary Fibrosis (IPF)

Start: 2022-06-30End: 2022-11-30Target: 20Updated: 2022-06-10

Phase 2

Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease

Angion Biomedica CorpGlomerular Disease, Proteinuria

Start: 2021-12-24End: 2023-08-31Target: 100Updated: 2022-03-23